ImmunityBio
VerifiedImmunityBio pioneers innovative therapies to conquer disease through immune system reprogramming.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$4.4b (Public information from Jun 2024)
Share price
$5.96 IBRX
Culver City California (HQ)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (73 %) | 54 % | (74 %) | 159 % | 1456 % | 775 % | 133 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (32253 %) | (33866 %) | (143324 %) | (62077 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (36670 %) | (37130 %) | (173570 %) | (93761 %) | (4513 %) | (362 %) | (93 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 23059 % | 20981 % | 103395 % | 37358 % | - | - | - |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
* | $300m | Post IPO Debt | |
| Total Funding | 000k | ||
Related Content
Recent News about ImmunityBio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.